MedTrace Logo

ENGAGE4HEALTH: A Combination Intervention Strategy for Linkage and Retention in Mozambique

NCT01930084 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2004

Last updated 2017-02-08

No results posted yet for this study

Summary

Purpose: To compare the effectiveness of a combination intervention strategy (CIS), consisting of point of care (POC) CD4+ testing immediately following HIV diagnosis and accelerated ART initiation for eligible participants delivered by facility personnel, and cellular appointment reminders delivered by study personnel, to the standard of care (SOC) on linkage to and retention in HIV care at 12 months among adults testing positive for HIV in Mozambique. Additionally, the protocol will assess the incremental effectiveness of CIS+ non-cash financial incentives (FI) compared to CIS without FI on study outcomes.

Conditions

Interventions

OTHER

Point of care CD4+ after HIV diagnosis

Point of care (POC) CD4+ testing immediately following HIV diagnosis

OTHER

Accelerated ART initiation

Accelerated ART initiation for eligible participants delivered by facility personnel

BEHAVIORAL

SMS appointment reminders

Cellular appointment reminders delivered by study personnel

OTHER

Non-cash Financial Incentives

Non-cash Financial Incentives

Sponsors & Collaborators

  • United States Agency for International Development (USAID)

    collaborator FED

  • Columbia University

    lead OTHER

Principal Investigators

  • Batya Elul, PhD, MSc · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Mozambique

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01930084 on ClinicalTrials.gov